Document Detail

Human or animal homograft: could they have a future as a biological scaffold for engineered heart valves?
MedLine Citation:
PMID:  20523298     Owner:  NLM     Status:  MEDLINE    
Tissue-engineered heart valves (TEHVs) promise to be the ideal heart valve replacement: they have the potential to grow and repair within the host, to minimise inflammatory and immunological responses and to limit thromboembolism. Viable cells included in TEHVs can theoretically adapt to a growing and changing environment exactly as a native biological structure. This could be extremely important in case of paediatric applications, where reoperations are frequently required to replace failed valve substitutes or to accommodate the growth of the patient. At present time the biological matrix from allogenic or xenogenic decellularized valves represents an appropriate valve scaffold in TEHVs, showing theoretically an ability to grow and repair within the host. Viable cells included in extracellular valve matrix can theoretically adapt to a growing and changing environment like the native biological structure. The aim of this paper is to present a review concerning the use of homograft and allograft valves as an ideal substrate for cardiac engineered tissue valves that represent an exciting possibility for in situ regeneration and repair of heart valves.
L Dainese; P Biglioli
Related Documents :
962398 - The surgical treatment of constrictive fibrous endocarditis.
3310938 - Thrombotic and bleeding complications of prosthetic heart valves.
7103448 - Rate of methicillin penetration into normal heart valve and experimental endocarditis l...
1389288 - Computer modelling of bioprosthetic heart valves.
24553388 - Cyclin a2 induces cardiac regeneration after myocardial infarction through cytokinesis ...
1443968 - Emotional support and survival after myocardial infarction. a prospective, population-b...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Journal of cardiovascular surgery     Volume:  51     ISSN:  0021-9509     ISO Abbreviation:  J Cardiovasc Surg (Torino)     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-04     Completed Date:  2010-10-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0066127     Medline TA:  J Cardiovasc Surg (Torino)     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  449-56     Citation Subset:  IM    
Department of Cardiac Surgery, University of Milan, Centro Cardiologico Monzino IRCCS, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Heart Valve Prosthesis*
Heart Valve Prosthesis Implantation / adverse effects,  instrumentation*
Heart Valves / growth & development,  immunology,  surgery*
Inflammation / immunology
Prosthesis Design
Tissue Engineering*
Tissue Scaffolds*
Transplantation, Heterologous
Transplantation, Homologous

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Improved patency and reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin com...
Next Document:  Biologically active breast milk proteins in association with very preterm delivery and stage of lact...